The proposed rule for U.S. clinical trial registration and results submission

New England Journal of Medicine

Volumn 372, Issue 2, 2015, Pages 174-180

  Zarin, Deborah A ^a   Tse, Tony ^a   Sheehan, Jerry ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INFORMATION DISSEMINATION; REGISTRATION; UNITED STATES; CLINICAL TRIAL (TOPIC); DEVICE APPROVAL; FACTUAL DATABASE; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; NATIONAL HEALTH ORGANIZATION; REGISTER; STANDARDS;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DEVICE APPROVAL; DRUG APPROVAL; GOVERNMENT REGULATION; NATIONAL INSTITUTES OF HEALTH (U.S.); REGISTRIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84920598363     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr1414226     Document Type: Article

References (25)

1. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
2. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
3. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71.
4. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.
5. Food and Drug Administration Amendments Act of 2007. Public Law 110-85. September 27, 2007 (http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf).
6. Notice of proposed rulemaking: clinical trials registration and results submission. Fed Regist 2014;79(225):69599-680 (https://federalregister.gov/a/2014-26197).
7. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects: adopted by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. Ferney-Voltaire, France: World Medical Association (http://www.wma.net/en/30publications/10policies/b3).
8. Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. JAMA 2014 November 19 (Epub ahead of print).
9. NIH request for public comments on the draft NIH policy on dissemination of NIH-funded clinical trial information. Bethesda, MD: National Institutes of Health, Department of Health and Human Services, November 19, 2014 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-019.html).
10. Laine C, Horton R, DeAngelis CD, et al. Clinical trial registration - looking back and moving ahead. N Engl J Med 2007; 356:2734-6.
11. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41.
12. Food and Drug Administration Modernization Act of 1997. Public Law 105-115 (http://www.gpo.gov/fdsys/pkg/PLAW-105publ115/pdf/PLAW-105publ115.pdf ).
13. McCray AT. Better access to information about clinical trials. Ann Intern Med 2000;133:609-14.
14. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials. gov results database - update and key issues. N Engl J Med 2011;364:852-60.
15. European Medicines Agency launches a new version of EudraCT: summary results of clinical trials soon to be available to the public. London: European Medicines Agency, 2013 (http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews-and- events%2Fnews%2F2013%2F10%2Fnews-detail-001918.jsp).
16. International Clinical Trials Registry Platform (ICTRP). Call for public consultation: WHO statement on public disclosure of clinical trial results. Geneva: World Health Organization, 2014 (http://www.who.int/ictrp/results/en).
17. Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. Official Journal of the European Union, 2012 (http://ec.europa.eu/health/files/eudralex/vol-10/2012-302-03/2012-302-03-en.pdf).
18. Draft guidance for industry - acne vulgaris: developing drugs for treatment. Rockville, MD: Food and Drug Administration, September 2005 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292.pdf).
19. International Clinical Trials Registry Platform (ICTRP). WHO trial registration data set (version 1.2.1). Geneva: World Health Organization (http://www.who.int/ictrp/network/trds/en).
20. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8.
21. Earley A, Lau J, Uhlig K. Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study. BMJ Open 2013; 3(1):pii:e001963.
22. Guidance for industry and investigators: safety reporting requirements for INDs and BA/BE studies. Rockville, MD: Food and Drug Administration, December 2012 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351.pdf).
23. Hillman SL, Mandrekar SJ, Bot B, et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol 2010;28: 3002-7.
24. What changes from current practice are proposed in the NPRM? Bethesda, MD: National Institutes of Health, Department of Health and Human Services, 2014 (http://www.regulations.gov/contentStreamer?objectId=090000648193837a&disposition=attachment&contentType=pdf).
25. NPRM at a glance: summary of key proposals. Rockville, MD: National Institutes of Health, Department of Health and Human Services, 2014 (http://www.regulations.gov/contentStreamer?objectId=090000648193837b&disposition=attachment&contentType=pdf).